PP.21.01

Abstract

Objective: Hypertension and diabetes are independent cardiovascular risk factors. In diabetic patients hypertension is frequent, and blood pressure targets are more strictly (below 140/85mmHg). Both hypertension and diabetes are associated with left ventricular hypertrophy and diastolic dysfunction. Patients with hypertension and diabetes are in high risk. ESC/ISH guidelines suggest the use of fixed-dose combination from the beginning of therapy in high risk hipertensives. The aim of our study was to evaluate the efficacy of fix full-dose combination perindopril/indapamide 10/2.5 mg on blood pressure, left ventricular hypertrophy, and diastolic dysfunction in patients with moderate hypertension and type2 diabetes. Design and method: We performed a prospective study, lasting 3 months, in which 34 grade 2 hypertensives with diabetes, medium age 56 ± 7 years, received once a day, fix full-dose combination perindopril/indapamide 10/2.5 mg. Office blood pressure was measured at baseline, 1 month and 3 months. The assessment of echocardiographic parameters of the left ventricle was performed at baseline and after 3 months of treatment. We assessed patient general condition or well-being as excellent, improved, appropriate or worse at baseline and after 3 months. Results: 91.2% of the patients reached blood pressure target. Both systolic (169 ± 15 vs 136 ± 12 mmHg, p < 0.01) and diastolic (105 ± 6.5 vs 83 ± 7 mmHg, p < 0.01) BP were significantly reduced. LVMI was decreased from138.5 ± 21 to 112.4 ± 18.9 g/m2 (p < 0.001). E/A ratio increased from 0.87 ± 0.26 to 1.08 ± 0.24 (p < 0.002). Relative wall thickness reduced from 0.49 ± 0.06 to 0.44 ± 0.07 (p < 0.05). After 3 months of therapy, patient well-being was rated as excellent in 52.9%, improved in 32.5%, appropriate in 11.7% and worse in 2.9%. Conclusions: Treatment with fix full-dose combination perindopril/indapamide 10/2.5 mg in moderate diabetic hypertensives proved a good control of blood pressure, rich the therapeutic target, and was accompanied by the regression of cardiac hypertrophy and improvement in left ventricular diastolic function. Treatment was well tolerated.